Deep Learning for Detecting BRCA Mutations in High-Grade Ovarian Cancer Based on an Innovative Tumor Segmentation Method From Whole Slide Images.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
PMID:

Abstract

BRCA1 and BRCA2 genes play a crucial role in repairing DNA double-strand breaks through homologous recombination. Their mutations represent a significant proportion of homologous recombination deficiency and are a reliable effective predictor of sensitivity of high-grade ovarian cancer (HGOC) to poly(ADP-ribose) polymerase inhibitors. However, their testing by next-generation sequencing is costly and time-consuming and can be affected by various preanalytical factors. In this study, we present a deep learning classifier for BRCA mutational status prediction from hematoxylin-eosin-safran-stained whole slide images (WSI) of HGOC. We constituted the OvarIA cohort composed of 867 patients with HGOC with known BRCA somatic mutational status from 2 different pathology departments. We first developed a tumor segmentation model according to dynamic sampling and then trained a visual representation encoder with momentum contrastive learning on the predicted tumor tiles. We finally trained a BRCA classifier on more than a million tumor tiles in multiple instance learning with an attention-based mechanism. The tumor segmentation model trained on 8 WSI obtained a dice score of 0.915 and an intersection-over-union score of 0.847 on a test set of 50 WSI, while the BRCA classifier achieved the state-of-the-art area under the receiver operating characteristic curve of 0.739 in 5-fold cross-validation and 0.681 on the testing set. An additional multiscale approach indicates that the relevant information for predicting BRCA mutations is located more in the tumor context than in the cell morphology. Our results suggest that BRCA somatic mutations have a discernible phenotypic effect that could be detected by deep learning and could be used as a prescreening tool in the future.

Authors

  • Raphaël Bourgade
    Department of Pathology, University Hospital of Nantes, Nantes, France. Electronic address: raphael.bourgade@gmail.com.
  • Noémie Rabilloud
    Laboratoire du Traitement du Signal et de l'Image - Inserm U1099, University of Rennes, Rennes, France.
  • Tanguy Perennec
    Department of Radiation Oncology, Institut de Cancérologie de l'Ouest Nantes, Saint-Herblain, France.
  • Thierry Pécot
    Department of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, 29407, USA.
  • Céline Garrec
    Department of Medical Genetics, University Hospital of Nantes, Nantes, France.
  • Alexis F Guédon
    National Institute of Health and Medical Research, Pierre Louis Institute of Epidemiology and Public Health, Sorbonne University, Paris, France.
  • Capucine Delnatte
    Department of Medical Genetics, University Hospital of Nantes, Nantes, France.
  • Stéphane Bézieau
    CHU Nantes, Service de Génétique Médicale, Nantes, France.
  • Alexandra Lespagnol
    Department of Molecular Genetics and Genomics, CHU Rennes, 35000, Rennes, France.
  • Marie de Tayrac
    Univ Rennes, Department of Molecular Genetics and Genomics, CHU Rennes, IGDR-UMR6290, CNRS, 35000, Rennes, France.
  • Sébastien Henno
    Department of Pathology, University Hospital of Rennes, Rennes, France.
  • Christine Sagan
    MESOPATH, MESONAT, MESOBANK Department of BioPathology Centre Leon Berard, Lyon, France; CHU Nantes, INSERM, Thorax Institute, Hôpital Laënnec CHU Nantes, Nantes, France.
  • Claire Toquet
    Department of Pathology, University Hospital of Nantes, Nantes, France.
  • Jean-François Mosnier
    Department of Pathology, University Hospital of Nantes, Nantes, France.
  • Solène-Florence Kammerer-Jacquet
    Department of Pathology, Rennes University Hospital, Rennes, France.
  • Delphine Loussouarn
    Department of Pathology, University Hospital of Nantes, Nantes, France.